225 related articles for article (PubMed ID: 36717825)
1. FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.
Quist-Løkken I; Andersson-Rusch C; Kastnes MH; Kolos JM; Jatzlau J; Hella H; Olsen OE; Sundan A; Knaus P; Hausch F; Holien T
Cell Commun Signal; 2023 Jan; 21(1):25. PubMed ID: 36717825
[TBL] [Abstract][Full Text] [Related]
2. FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes.
Pettinato M; Dulja A; Colucci S; Furiosi V; Fette F; Steinbicker AU; Muckenthaler MU; Nai A; Pagani A; Silvestri L
Am J Hematol; 2023 Aug; 98(8):1223-1235. PubMed ID: 37199280
[TBL] [Abstract][Full Text] [Related]
3. BMPR2 inhibits activin and BMP signaling via wild-type ALK2.
Olsen OE; Sankar M; Elsaadi S; Hella H; Buene G; Darvekar SR; Misund K; Katagiri T; Knaus P; Holien T
J Cell Sci; 2018 Jun; 131(11):. PubMed ID: 29739878
[TBL] [Abstract][Full Text] [Related]
4. The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.
Colucci S; Pagani A; Pettinato M; Artuso I; Nai A; Camaschella C; Silvestri L
Blood; 2017 Nov; 130(19):2111-2120. PubMed ID: 28864813
[TBL] [Abstract][Full Text] [Related]
5. A functional interplay between the two BMP-SMAD pathway inhibitors TMPRSS6 and FKBP12 regulates
Pettinato M; Aghajan M; Guo S; Bavuso Volpe L; Carleo R; Nai A; Pagani A; Altamura S; Silvestri L
Am J Physiol Gastrointest Liver Physiol; 2024 Mar; 326(3):G310-G317. PubMed ID: 38252872
[TBL] [Abstract][Full Text] [Related]
6. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension.
Spiekerkoetter E; Tian X; Cai J; Hopper RK; Sudheendra D; Li CG; El-Bizri N; Sawada H; Haghighat R; Chan R; Haghighat L; de Jesus Perez V; Wang L; Reddy S; Zhao M; Bernstein D; Solow-Cordero DE; Beachy PA; Wandless TJ; Ten Dijke P; Rabinovitch M
J Clin Invest; 2013 Aug; 123(8):3600-13. PubMed ID: 23867624
[TBL] [Abstract][Full Text] [Related]
7. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
[TBL] [Abstract][Full Text] [Related]
8. ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex.
Williams E; Riesebos E; Kerr G; Bullock AN
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33572801
[TBL] [Abstract][Full Text] [Related]
9. Competition between type I activin and BMP receptors for binding to ACVR2A regulates signaling to distinct Smad pathways.
Szilágyi SS; Amsalem-Zafran AR; Shapira KE; Ehrlich M; Henis YI
BMC Biol; 2022 Feb; 20(1):50. PubMed ID: 35177083
[TBL] [Abstract][Full Text] [Related]
10. Alk2/ACVR1 and Alk3/BMPR1A Provide Essential Function for Bone Morphogenetic Protein-Induced Retinal Angiogenesis.
Lee HW; Chong DC; Ola R; Dunworth WP; Meadows S; Ka J; Kaartinen VM; Qyang Y; Cleaver O; Bautch VL; Eichmann A; Jin SW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):657-663. PubMed ID: 28232325
[TBL] [Abstract][Full Text] [Related]
11. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
Olsen OE; Wader KF; Hella H; Mylin AK; Turesson I; Nesthus I; Waage A; Sundan A; Holien T
Cell Commun Signal; 2015 Jun; 13():27. PubMed ID: 26047946
[TBL] [Abstract][Full Text] [Related]
12. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
Mitrofan CG; Appleby SL; Nash GB; Mallat Z; Chilvers ER; Upton PD; Morrell NW
J Biol Chem; 2017 Aug; 292(33):13714-13726. PubMed ID: 28646109
[TBL] [Abstract][Full Text] [Related]
13. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
[TBL] [Abstract][Full Text] [Related]
14. Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.
Olsen OE; Hella H; Elsaadi S; Jacobi C; Martinez-Hackert E; Holien T
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32235336
[TBL] [Abstract][Full Text] [Related]
15. A Bone Morphogenetic Protein (BMP)-derived Peptide Based on the Type I Receptor-binding Site Modifies Cell-type Dependent BMP Signalling.
Tong Z; Guo J; Glen RC; Morrell NW; Li W
Sci Rep; 2019 Sep; 9(1):13446. PubMed ID: 31530856
[TBL] [Abstract][Full Text] [Related]
16. Activation of BMP Signaling by FKBP12 Ligands Synergizes with Inhibition of CXCR4 to Accelerate Wound Healing.
Peiffer BJ; Qi L; Ahmadi AR; Wang Y; Guo Z; Peng H; Sun Z; Liu JO
Cell Chem Biol; 2019 May; 26(5):652-661.e4. PubMed ID: 30827938
[TBL] [Abstract][Full Text] [Related]
17. FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor.
Yamaguchi T; Kurisaki A; Yamakawa N; Minakuchi K; Sugino H
J Mol Endocrinol; 2006 Jun; 36(3):569-79. PubMed ID: 16720724
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic proteins.
Chen D; Zhao M; Mundy GR
Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
[TBL] [Abstract][Full Text] [Related]
19. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of bone morphogenetic protein binding sites and Smad1/5 activation in human vascular cells.
Upton PD; Long L; Trembath RC; Morrell NW
Mol Pharmacol; 2008 Feb; 73(2):539-52. PubMed ID: 17989347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
